The stock of Abbott Laboratories (ABT) has seen a 2.48% increase in the past week, with a 0.99% gain in the past month, and a 13.05% flourish in the past quarter. The volatility ratio for the week is 3.88%, and the volatility levels for the past 30 days are at 2.77% for ABT. The simple moving average for the past 20 days is 0.13% for ABT’s stock, with a 8.74% simple moving average for the past 200 days.
Is It Worth Investing in Abbott Laboratories (NYSE: ABT) Right Now?
The price-to-earnings ratio for Abbott Laboratories (NYSE: ABT) is 16.70x, which is above its average ratio. Moreover, the 36-month beta value for ABT is 0.75. Analysts have varying opinions on the stock, with 13 analysts rating it as a “buy,” 7 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for ABT is 1.72B and currently, short sellers hold a 1.27% of that float. On April 15, 2025, ABT’s average trading volume was 7.32M shares.
ABT) stock’s latest price update
Abbott Laboratories (NYSE: ABT)’s stock price has plunge by 0.85relation to previous closing price of 126.88. Nevertheless, the company has seen a 2.48% surge in its stock price over the last five trading sessions. zacks.com reported 2025-04-14 that The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
Analysts’ Opinion of ABT
Many brokerage firms have already submitted their reports for ABT stocks, with Oppenheimer repeating the rating for ABT by listing it as a “Outperform.” The predicted price for ABT in the upcoming period, according to Oppenheimer is $130 based on the research report published on October 08, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ABT reach a price target of $131. The rating they have provided for ABT stocks is “Overweight” according to the report published on September 19th, 2024.
ABT Trading at -2.20% from the 50-Day Moving Average
After a stumble in the market that brought ABT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.40% of loss for the given period.
Volatility was left at 2.77%, however, over the last 30 days, the volatility rate increased by 3.88%, as shares surge +0.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.02% upper at present.
During the last 5 trading sessions, ABT rose by +2.48%, which changed the moving average for the period of 200-days by +22.01% in comparison to the 20-day moving average, which settled at $127.80. In addition, Abbott Laboratories saw 13.13% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABT starting from Earnhardt Lisa D, who sale 91,167 shares at the price of $133.82 back on Mar 06 ’25. After this action, Earnhardt Lisa D now owns 71,928 shares of Abbott Laboratories, valued at $12,199,968 using the latest closing price.
Earnhardt Lisa D, the EVP AND GROUP PRESIDENT of Abbott Laboratories, sale 200 shares at $136.65 during a trade that took place back on Mar 07 ’25, which means that Earnhardt Lisa D is holding 71,928 shares at $27,329 based on the most recent closing price.
Stock Fundamentals for ABT
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.56 for the gross margin
The net margin for Abbott Laboratories stands at 0.32. The total capital return value is set at 0.1. Equity return is now at value 30.96, with 17.27 for asset returns.
Based on Abbott Laboratories (ABT), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at 0.57. The debt to equity ratio resting at 0.32. The interest coverage ratio of the stock is 17.49.
Currently, EBITDA for the company is 10.83 billion with net debt to EBITDA at 0.68. When we switch over and look at the enterprise to sales, we see a ratio of 5.47. The receivables turnover for the company is 4.42for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.67.
Conclusion
To wrap up, the performance of Abbott Laboratories (ABT) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
